Slate Path Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
|
|||||
|
2020
Q3 | $31M | Sell |
|
|||||
|
2020
Q2 | $86.5M | Sell |
|
|||||
|
2020
Q1 | $78.2M | Sell |
|
|||||
|
2019
Q4 | $93.9M | Buy |
|
|||||
|
2019
Q3 | $49.5M | Hold |
|
|||||
|
2019
Q2 | $44.6M | Buy |
|
|||||
|
2019
Q1 | $44.9M | Hold |
|
|||||
|
2018
Q4 | $35M | Hold |
|
|||||
|
2018
Q3 | $42M | Hold |
|
|||||
|
2018
Q2 | $47.3M | Buy |
|
|||||
|
2018
Q1 | $44.7M | Sell |
|
|||||
|
2017
Q4 | $56.8M | Sell |
|
|||||
|
2017
Q3 | $65.9M | Sell |
|
|||||
|
2017
Q2 | $90.5M | Sell |
|
|||||
|
2017
Q1 | $103M | Hold |
|
|||||
|
2016
Q4 | $74.9M | Buy |
|
|||||
|
2016
Q3 | $83M | Buy |
|
|||||
|
2016
Q2 | $63M | Hold |
|
|||||
|
2016
Q1 | $71.2M | Buy |
|
|||||
|
2015
Q4 | $68.3M | Buy |
|
|||||
|
2015
Q3 | $47.8M | Sell |
|
|||||
|
2015
Q2 | $81.7M | Sell |
|
|||||
|
2015
Q1 | $89.3M | Hold |
|
|||||
|
2014
Q4 | $82.9M | Hold |
|
|||||
|
2014
Q3 | $66.8M | Buy |
|
|||||
|
2014
Q2 | $37.8M | Buy |
|
|||||
|
2014
Q1 | $27.6M | Sell |
|
|||||
|
2013
Q4 | $64.3M | Sell |
|
|||||
|
2013
Q3 | $80.7M | Buy |
|
|||||
|
2013
Q2 | $32.5M | Buy |
|